Joly F, Fabbro M, Follana P, Lequesne J, et al. A phase II study of Navitoclax (ABT-263) as single agent in women heavily pretreated for recurrent epithelial ovarian cancer: The MONAVI - GINECO study. Gynecol Oncol 2022 Feb 2. pii: S0090-8258(22)00048.
PMID: 35123771